Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open in the green
Thu, 18 Sep 09:30 am

Asian stock markets have opened the day on a mixed note with the markets in Japan (up 1.3%) and China (up 0.4%) leading the gains. However, the markets in Hong Kong (down 0.7%) and South Korea (down 0.7%) are trading in the red. The Indian share markets have opened the day on a positive note. Barring the IT index, all sectoral indices are trading firm with healthcare and consumer durables indices leading the gains.

The Sensex today is higher by around 131 points (0.5%), while the NSE-Nifty is up by about 42 points (0.5%). The mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.6% and 1.2% respectively. The rupee is currently trading at Rs 60.95 to the US dollar.

FMCG stocks have opened the day mainly in the green with Archies Ltd and Kokuyo Camlin leading the gains. As per a leading financial daily, FMCG company Dabur India has launched wearable mosquito repellent products, including wristbands and patches, under its Odomos brand. In addition, it has also inked an agreement with Pogo under which Odomos will use the image of Pogo's character Chota Bheem to adorn the wristband and mosquito repellent patches. In a statement, the company has said that this new range is India's first range of 100% natural active wearable mosquito repellents. Moreover, the wristband and patch are both water resistant. The Odomos mosquito repellent wristband is priced at Rs 199. This can last up to 15 days. The Odomos Patches aim to provide protection from mosquitoes for 12 hours. They are available in two packs of 10 and 24 priced at Rs 120 and Rs 265 respectively.

Indian Pharma stocks have opened the day on a firm note with Elder Pharma Ltd and J.B.Chemicals Ltd leading the gains. In a filing with the BSE, Gurgaon-based drug maker Ranbaxy Laboratories has stated that it has received a Civil Investigation Demand (CID) from the US Department of Justice. The department has sought information relating to the manner in which the company reports pricing data for certain products eligible for reimbursement under the Medicaid program. The company has clarified that the CID is a request for documents and information. It is not an allegation of wrongdoing or demand for compensation. It must be noted that Ranbaxy has been penalized by US authorities in the past.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.